title: Evaluation of efficacy of acarbose on glucose fluctuation and postprandial glucose using continuous glucose monitoring in type 2 diabetes mellitus.
abstract: BACKGROUND
  The objective of this study was to evaluate the effects of the α-glucosidase inhibitor acarbose on glucose fluctuations in patients with type 2 diabetes using continuous glucose monitoring (CGM).
  
  
  METHODS
  CGM was performed for 4 days (72 h), and acarbose at 300 mg/day was administered on two of these days but not on the other two days. The effects on blood glucose fluctuations were evaluated.
  
  
  RESULTS
  We recruited a total of 10 patients (five men and five women) with a mean ± SD age of 63.1 ± 12.1 years, body mass index of 22.6 ± 5.4 kg/m(2), and glycohemoglobin of 9.9 ± 1.9%. During treatment with acarbose, significant decreases in median (range) SD of 24-h mean blood glucose (22.48 [6.39-47.22] mg/dL vs. 32.78 [18.83-58.93] mg/dL, P = 0.004), 24-h blood glucose fluctuations (453.27 [128.51-903.94] mg·h/dL vs. 677.05 [358.03-1,234.57] mg·h/dL, P = 0.002), and mean amplitude of glycemic excursions (65.00 [18.17-117.50] vs. 97.09 [53.00-166.67], P = 0.010) occurred compared with no treatment.
  
  
  CONCLUSIONS
  Acarbose reduced excessive blood glucose fluctuations.
authors.affiliation: Division of Diabetes and Endocrinology, Department of Internal Medicine, Jikei University Daisan Hospital, Komae, Tokyo, Japan. moriyutakajp@yahoo.co.jp
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Mori
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Shiozaki
authors.forename: Kenichi
authors.initials: K
authors.lastname: Matsuura
authors.forename: Takaaki
authors.initials: T
authors.lastname: Tanaka
authors.forename: Junichi
authors.initials: J
authors.lastname: Yokoyama
authors.forename: Kazunori
authors.initials: K
authors.lastname: Utsunomiya
mesh_terms: D020909:Acarbose / Q000627:therapeutic use*; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D019518:Postprandial Period; D018709:Statistics, Nonparametric
chemical_list: D020909:Acarbose; D001786:Blood Glucose; D004791:Enzyme Inhibitors; D006442:Glycated Hemoglobin